Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amlodipine besylate + benazepril hydrochloride is a fixed-dose combination oral medication used to treat high blood pressure (hypertension). It combines two antihypertensive agents with complementary mechanisms of action. Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in vasodilation and reduced blood pressure. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, leading to vasodilation and decreased aldosterone-mediated water retention. The combination provides additive antihypertensive effects by targeting different pathways involved in blood pressure regulation[1][3][6]. The primary indication for this drug is the management of hypertension to reduce the risk of cardiovascular events such as stroke or heart attack[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amlodipine besylate + benazepril hydrochloride.